"Adenovirus-Mediated Delivery of p16 to p16-Deficient Human Bladder Cancer Cells Confers Chemoresistance to cisplatin and Paclitaxel."

According to the authors' abstract of an article published in Clinical Cancer Research, "We have previously established the efficacy of adenoviral gene delivery vectors for the treatment of bladder carcinoma in vivo. In the present work, we developed a gene therapy strategy for bladder cancer based on the replacement of the tumor suppressor p16, which is known to be mutated or deleted in a variety of human tumors, including those derived from the bladder. Previous reports have demonstrated that reconstitution of p16 has marked effects on the proliferative capacity of tumor cell lines both in vitro and in vivo, and that p16 expression causes resistance to some...

Want to see the full article?

• Purchase this article for only $3.00